Stock KNTE KINNATE BIOPHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Kinnate Biopharma Inc.

Equities

KNTE

US49705R1059

Delayed Nasdaq
Other stock markets
 16:00:00 2024-04-02 EDT 		5-day change 1st Jan Change
2.65 USD -0.38% Intraday chart for Kinnate Biopharma Inc. -.--% +11.81%
06-13 Kinnate Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-03 Kinnate Biopharma Inc. Announces Board Resignations CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Kinnate Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Kinnate Biopharma Inc. Announces Board Resignations
CI
XOMA Corporation Announces Closing of Tender Offer
AQ
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index
CI
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..
CI
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from S&P TMI Index
CI
North American Morning Briefing : Stocks Seen -2-
DJ
Kinnate Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Markets Steady -2-
DJ
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
AQ
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
BU
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
AQ
Kinnate Biopharma Sells Cancer Treatment Assets to Pierre Fabre Laboratories
MT
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories
PR
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
AQ
Stifel Raises Kinnate Biopharma's Price Target to $2.59 From $1.50, Keeps Hold Rating
MT
KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
BU
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash per Share plus a Contingent Value Right
AQ
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.
PR
Sector Update: Health Care Stocks Advance Friday Afternoon
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KNTE Stock
  4. News Kinnate Biopharma Inc.